Subjective measurements
Short-term opioid use can cause sedation and daytime drowsiness [
130,
159,
216,
217]. Dizziness and sleepiness are common side effects of opioid pain medications [
41,
109]. With a stable dose, tolerance to the subjective, sedative effects of opioids develops within 2–3 days and some studies find that cognition normalizes after that [
103,
129], supporting the notion of tolerance to the sedative effects. However, there is also evidence that unpleasant sedative effects, decreased alertness and increased reaction time in a variety of cognitive tasks continue to be experienced by some patients on a stable dose of narcotic medication [
23,
24,
54,
181]. These differences in findings may be related to inconsistencies in how the sedative effects are defined [
217].
Xiao et al. [
215] studied the quality of sleep in persons with heroin use disorder on early methadone maintenance therapy (MMT) after a median of 5.4 days of treatment [
215]. Patients without pre-existing chronic sleep disturbances demonstrated lower ratings of sleep (Pittsburgh Sleep Quality Index [PSQI]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]) compared to healthy sleepers. Oyefeso et al. [
151] reported inadequate sleep quality and quantity as well as difficulty initiating and maintaining sleep in persons with opioid use disorders in early stages of methadone detoxification. Similar studies have shown some increased daytime drowsiness and below normal sleep measures in this patient population [
113,
114,
134,
204]. After longer periods of MMT, however, there is some degree of tolerance to these effects [
206], and sleep difficulty is shown to be present only in the first 6–12 months of MMT [
158,
193].
There is a limited number of reports studying the effects of withdrawal and abstinence from chronic opiate use. Asaad et al. reported insomnia, hypersomnolence, increased sleep latency, and reduced sleep duration in individuals with opioid use disorder after 3 weeks of abstinence [
17].
Objective measurements
Sleep architecture in healthy adults can be significantly altered even after a single dose of oral opioids [
67]. Using electroencephalography (EEG) and electromyography (EMG), Kay et al. [
117] reported that acute intoxication with heroin, morphine, or methadone resulted in dose-dependent enhancements in arousal during sleep–wake periods. Heroin use demonstrated a stronger effect particularly on reduction of theta waves and REM sleep [
117,
204]. Morphine and methadone reduce slow-wave sleep and in-crease stage 2 sleep [
67]. Several studies have shown that acute use of various opioids results in increased REM latency [
115,
159], decreased REM sleep time [
113‐
117,
130,
159,
180], increased stage 1 [
67,
130,
180] and stage 2 sleep [
67], and decreased slow-wave sleep [
113‐
117,
159]. Acute use of opioids also leads to increased sleep latency [
116,
130], increased wakefulness after sleep onset (WASO) [
113‐
117,
130,
159,
215], and concomitant decreases in total sleep time (TST) [
116,
215] and sleep efficiency (SE) [
116,
159,
215].
There is a partial tolerance to the effects of opioids with some evidence for increased REM sleep time in acute use [
113,
114,
130], and less pronounced changes in SWS, wakefulness, and arousal observed after chronic use. However, vocalization during REM sleep, delta bursts, and increased daytime sleepiness may be observed in this phase [
204]. Tolerance to sleep problems is more prominent in MMT [
113,
134,
159,
204], with evidence that persons in treatment for more than 12 months exhibit better recovery sleep following sleep deprivation than persons in shorter-term treatment [
193].
Nevertheless, abnormal PSG findings are commonly reported in chronic opioid users despite development of tolerance. These abnormalities include increased sleep latency [
100,
185], increased awakening [
100,
113,
185,
190], decreased total sleep time [
100,
185], and decreased sleep efficiency [
100,
190]. Slow-wave sleep time [
113,
114,
185,
190] and REM sleep are decreased compared to baseline [
113,
185,
190,
205], while duration of stage 2 sleep is increased similar to acute use [
190,
205]. Analysis of actigraphy data from patients with prescription opioid use disorders indicated poor sleep in terms of total sleep time, sleep efficiency, sleep latency, total time awake, and time spent moving [
100].
Several studies have reported changes in patterns of sleep with progressive abstinence from opiates. At around 5–7 days of acute abstinence from chronic heroin use, Howe et al. reported decreased total sleep time, slow-wave sleep, REM, and stage 2 sleep and increased sleep latency, wake after sleep onset, and REM latency compared to healthy sleepers [
101] (Table
2). During the first 3 weeks of abstinence, prolonged sleep latency, decreased sleep efficiency, decreased TST, increased arousal index, increased stage 1 and 2, and decreased slow-wave sleep (SWS) were prominent compared to healthy sleepers [
17] (Table
2). After 6 weeks and up to 6 months of abstinence from methadone, there is a rebound increase in SWS and REM time to a higher level than baseline [
113,
114,
134].
Relationship between subjective and objective outcomes
Using PSG data, Xiao et al. showed an inverse relationship between the Epworth Sleepiness Scale (ESS) scores and SWS time in patients with heroin use disorder who were in early methadone treatment [
215]. They reported poor initial quality of sleep based on the PSQI scores which were significantly correlated with their methadone dosages [
102]. PSQI score were also found to be significantly correlated with average diary-reported sleep time, subjective ratings of feeling rested, and PSG sleep efficiency in MMT patients [
179]. Overall the high prevalence of sleep complaints in this population along with documented abnormal objective findings argue that these complaints are more likely to be secondary to pathology rather than sleep misperception.
Pharmacotherapy options targeting sleep abnormalities
Modifiable psychological and medical risk factors associated with sleep disturbance should be identified and corrected in order to improve quality of life in drug treatment. Treatment of sleep disorders among MMT patients, particularly in those with psychiatric disorders, benzodiazepine abuse, chronic pain, and patients who are on high methadone dose is of crucial importance.
Methadone
Methadone maintenance is widely used and a standard pharmacotherapy for treating patients with opioid use disorders [
18,
68,
71,
197,
220]. Chronic methadone use is more commonly associated with tolerance to the sleep problems compared to other opioids [
113,
134,
159,
204]. However, more than three-quarters of persons receiving methadone maintenance therapy (MMT) still report sleep complaints [
151,
156,
186]. This is complicated by the fact that about 50 % of MMT patients report use of both illicit drugs and legal medications to help with sleep [
156,
186]. Methadone and electrostimulation (ES) have been used to treat insomnia in the first 30 days of opioid withdrawal [
84]. In the first 2 weeks of withdrawal patients treated with electrostimulation had shorter sleep time and more awakenings than patients receiving methadone. They also found that subjects in the ES group who remained in treatment experienced more sleep disturbance than those who dropped out prematurely. Overall methadone and ES were not efficient in treating insomnia associated with withdrawal. Stein et al. tested whether trazodone (50 mg/night), one of the most commonly prescribed medications for treatment of insomnia, improved sleep among methadone-maintained persons with PSQI score of six or higher [
187]. They found that trazodone did not improve subjective or objective sleep problems in this group of patients.
Buprenorphine
Buprenorphine was FDA approved as a pharmacotherapy for opioid use disorders in 2002. Buprenorphine has the advantage of being available from office-based practices [
131]. There are limited numbers of studies looking at the effect of buprenorphine on sleep. One study suggests that buprenorphine is comparable to methadone in improving sleep quality in patients involved in long-term treatment [
133]. In another study, forty-two patients with opiate use disorder were treated with either methadone or buprenorphine and gradually tapered down over the course of 2–3 weeks. Buprenorphine-treated patients had 2.5 % lower sleep efficiency and 9 % shorter actual sleep time. These significant group differences were most pronounced with the lowest doses toward the late withdrawal phase [
161]. The time course of tapering buprenorphine during detoxification might also play a role in the quantity of sleep. A randomized controlled trial of buprenorphine for detoxification from prescription opioid use evaluated sleep time among patients assigned to receive 1, 2, and 4-week buprenorphine tapers. The 4-week taper group reported significantly less loss of sleep compared to the other groups [
70].
In a study of 70 patients with chronic opioid use, the effect of buprenorphine on sleep disordered breathing was measured polysomnographically [
72]. Patients in this study tended to be young (mean age of 31.8) and non-obese (mean body mass index 24.9 ± 5.9). However, treatment with buprenorphine was associated with mild to severe sleep-disordered breathing in this population, with a substantial rate of associated hypoxemia [
72].
Although information on the effect of other medications on sleep in chronic opiate users is limited, Srisurapanont and Jarusuraisin [
184] explored the effect of amitriptyline (57.7 ± 12/night) versus lorazepam (2.1 ± 0.5/night) to treat insomnia in 27 patients with opioid withdrawal in a randomized double-blind study [
184]. The Sleep Evaluation Questionnaire and three insomnia items of the Hamilton Depression Rating Scale were used to assess sleep. All aspects of sleep (including ease of getting to sleep, perceived quality of sleep, integrity of early morning behavior following wakefulness and Hamilton Depression Rating Scale insomnia items), except for ease of awakening from sleep, were not significantly different in the two treatment groups. These findings suggest that apart from the hangover effect, amitriptyline is as effective as lorazepam in the treatment of opioid-withdrawal insomnia.